CYTK

Cytokinetics Inc

$84.88 -0.68 (-0.79%) At close · Jul 8

Market Cap

$10.56B

124,432,565

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Poor Quant / Vol Moderate

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +29%

above

Price vs 50-day avg +13%

above

RSI (14) 65

neutral

MACD trend Positive

52-week position 94%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +25%

trailing

6-month return +34%

trailing

YTD return +34%

this year

Relative strength +27%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $75 › 200d $66 — 50d above 200d

Institutional flow Distributing

10 of 450 funds reported for Jun 30 · net -28.5K sh shares · +2 new

Insider flow Distributing

Net -$11.8M over 90 days · 100% sells

Short interest Falling

11.87% of float · ▼ -4.7% MoM · 9.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

450 holders — near 3-yr high, broad support

Squeeze score 86

high risk · 0–100

Fundamentals

Poor

Revenue growth −87%

Y/Y

EPS growth −24%

Y/Y

Free cash flow $-534.8M

Balance sheet $497.0M

net debt

Quant / Vol

risk profile

Moderate

Volatility 61%

annualized · 1-yr

Max drawdown −15%

past year

ATR 3.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Aug 5, 2026 Est · unconfirmed · in 4 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 5, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+29% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

65 Neutral

MACD trend

Positive Bullish

52-week position

94% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $75 › 200d $66 — 50d above 200d

Institutional flow Distributing

10 of 450 funds reported for Jun 30 · net -28.5K sh shares · +2 new

Insider flow Distributing

Net -$11.8M over 90 days · 100% sells

Short interest Falling

11.87% of float · ▼ -4.7% MoM · 9.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

450 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $33 Now $85 · 94% 52-wk high $88

vs 200-day avg +29% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
HCPs REMS certified	1,400	Q1 2026	—
Patients on therapy on paid prescription	70%	Q1 2026	—
Patients prescribed MYQORZO	680	Q1 2026	—
Unique healthcare providers prescribed MYQORZO	275	Q1 2026	—
average prescriptions per HCP	2.4	Q1 2026 call	—
average prescriptions per high-volume HCP	2.6	Q1 2026 call	—
HCPs prescribing MYCorzo through April	425	through April 2026 call	—
MYCorzo patient community enrollment	2,100	Q1 2026 call	—
new-to-brand Q1 exit share	30%	Q1 2026 call	—
patients prescribed MYCorzo	680	Q1 2026 call	—
patients prescribed MYCorzo through April	1,100	through April 2026 call	—
unique HCPs prescribing MYCorzo	275	Q1 2026 call	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CYTK Cytokinetics Inc this stock	$10.56B	+33.6%	-87.4%	—	11.9%
ONC BeOne Medicines Ltd.	$446.53B	+1.7%	+22179.2%	908.7	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$126.50B	+9.9%	+46.2%	29.6	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.50B	-14.0%	+20.8%	16.5	3.2%
ARGX Argenx SE	$57.20B	+8.8%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

451

% held: 121.2%
Reported: 10 of 450
Top holder: T. Rowe Price Investment…

Held Float

View

Held by Funds

Fund positions

489

View

Short & Settlement

Short Interest Falling

Shares short

14.8M

Days to cover: 9.3d
Change: -734.4K sh

View

Short Volume

Short vol %

64%

As of: Jul 8, 2026

Short Total

View

Fails to Deliver

FTD shares

3.1K

Value: $219.2K
As of: Jun 8, 2026

View

Off-Exchange

Off-exchange %

47.8%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$11.8M

Buyers / Sellers: 0 / 8

Buyers Sellers

View

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: Jun 30, 2026

View

Financials

Revenue (FY)

$88.0M

Net income (FY): $-785.0M
EPS diluted: $-6.54

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 13

View

Proposed Sales

Value

$2.1M

Shares: 24.5K
Filed: Jul 7, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 8, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CYTK	-0.4%	+25.0%	+34.0%	-0.4%	+33.6%
SPY	-0.2%	+0.8%	+7.4%	-0.2%	+9.3%
vs SPY	-0.2%	+24.2%	+26.6%	-0.2%	+24.3%

Key facts CIK 1061983 CUSIP 23282W605 13F (30d) 13 filings 12 filers Visit website Investor relations

CYTK

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance